Skip to main content
Journal cover image

Use of bevacizumab in recurrent glioblastoma.

Publication ,  Journal Article
Ghiaseddin, A; Peters, KB
Published in: CNS Oncol
2015

Glioblastoma (GBM) is the most common adult primary brain neoplasm. Despite advances in treatment, GBM continues to be associated with considerable morbidity and mortality as compared with other malignancies. Standard treatment for GBM results in survival of 12.9 months (95% CI: 12.3-13.7 months) with a median progression-free survival of 7.2 months (95% CI: 6.4-8.2 months) in a modern GBM cohort. These aggressive tumors recur and treatment for recurrent GBM continues to have very poor outcomes. Prior to the use of bevacizumab, monoclonal antibody to VEGF, 6-month progression-free survival in clinical trials for recurrent GBM ranged from 9 to 15%. Trials utilizing bevacizumab and its subsequent US FDA approval have given more hope to recurrent GBM and this concise review discusses bevacizumab in recurrent GBM. This review focuses on time-to-event outcomes (overall survival, progression-free survival and 6-month progression-free survival) in clinical trials utilizing bevacizumab for the treatment of recurrent GBM. For this review, we have chosen to focus primarily on Phase II clinical trials that have been published and available in the literature (PubMed). While we focused primarily on time-to-event variables, toxicity and safety of bevacizumab is very important and this agent can be associated with serious life-threatening toxicities. We have included a general section of toxicities but for a more lengthy review please see the excellent study by Odia and colleagues.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

CNS Oncol

DOI

EISSN

2045-0915

Publication Date

2015

Volume

4

Issue

3

Start / End Page

157 / 169

Location

England

Related Subject Headings

  • Male
  • Humans
  • Glioblastoma
  • Female
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Bevacizumab
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ghiaseddin, A., & Peters, K. B. (2015). Use of bevacizumab in recurrent glioblastoma. CNS Oncol, 4(3), 157–169. https://doi.org/10.2217/cns.15.8
Ghiaseddin, Ashley, and Katherine B. Peters. “Use of bevacizumab in recurrent glioblastoma.CNS Oncol 4, no. 3 (2015): 157–69. https://doi.org/10.2217/cns.15.8.
Ghiaseddin A, Peters KB. Use of bevacizumab in recurrent glioblastoma. CNS Oncol. 2015;4(3):157–69.
Ghiaseddin, Ashley, and Katherine B. Peters. “Use of bevacizumab in recurrent glioblastoma.CNS Oncol, vol. 4, no. 3, 2015, pp. 157–69. Pubmed, doi:10.2217/cns.15.8.
Ghiaseddin A, Peters KB. Use of bevacizumab in recurrent glioblastoma. CNS Oncol. 2015;4(3):157–169.
Journal cover image

Published In

CNS Oncol

DOI

EISSN

2045-0915

Publication Date

2015

Volume

4

Issue

3

Start / End Page

157 / 169

Location

England

Related Subject Headings

  • Male
  • Humans
  • Glioblastoma
  • Female
  • Clinical Trials as Topic
  • Brain Neoplasms
  • Bevacizumab
  • Angiogenesis Inhibitors
  • 3211 Oncology and carcinogenesis